Enanta Pharmaceuticals | Passifs Courants





Passifs Courants Changement Date
AbbVie USD 43.29B 3.9B 2025-12
Amgen USD 25.49B 3.7B 2025-12
Anika Therapeutics USD 19.09M 3.01M 2025-09
Arrowhead Research USD 347.42M 151.94M 2025-12
AstraZeneca USD 30.62B 3.44B 2025-12
BioCryst Pharmaceuticals USD 190.24M 13.08M 2025-09
Biogen USD 3.35B 59.4M 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
GlaxoSmithKline GBP 21.39B 57M 2025-12
Halozyme Therapeutics USD 177.09M 660.14M 2025-12
Heron Therapeutics USD 89.71M 168.89M 2025-09
Immunic USD 30.08M 2.77M 2025-09
Incyte USD 1.52B 176.44M 2025-12
Insmed USD 468.87M 51.66M 2025-12
Ionis Pharmaceuticals USD 783M 120.46M 2025-12
J&J USD 54.13B 3.26B 2025-12
Karyopharm Therapeutics USD 87.16M 12.06M 2025-09
Ligand Pharmaceuticals USD 37.45M 6.91M 2025-12
Merck USD 28.63B 2.59B 2025-09
Neurocrine Biosciences USD 743.4M 105.4M 2025-12
Novartis USD 32B 286M 2025-09
Novavax USD 429.87M 40.73M 2025-09
Pfizer USD 36.6B 1.13B 2025-09
PTC Therapeutics USD 968.43M 102.18M 2025-12
Roche Holding CHF 28B 421M 2025-12
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
Vertex Pharmaceuticals USD 3.86B 614.1M 2025-12


Enanta Pharmaceuticals Passifs Courants - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2026.